Linzess costs around $280 to $315 for a 30-day supply without insurance, making it one of the pricier medications for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Several factors drive that price: patent protection that blocks generic competition, a revenue-sharing deal between two pharmaceutical companies, and the broader dynamics of U.S. drug pricing that keep brand-name medications far above international prices.
Patent Protection Blocks Generic Competition
The single biggest reason Linzess remains expensive is that no generic version is available in the United States. The drug is protected by multiple patents with staggered expiration dates, a common strategy that extends a brand-name drug’s market exclusivity well beyond its original patent. Several of the earliest patents expired in January 2024, but others stretch to 2031 and one runs as late as August 2033.
Without generics on the market, there’s no price competition. Ironwood Pharmaceuticals and AbbVie, which co-market the drug in North America, can set the price knowing patients have no cheaper bioequivalent option at the pharmacy counter. A settlement between the companies and Teva Pharmaceuticals will allow Teva to launch generic 145 mcg and 290 mcg versions of Linzess beginning March 31, 2029, assuming FDA approval. The lowest-dose 72 mcg capsule could potentially see generic competition sooner, since its last relevant patent expires in 2026 (with a possible pediatric extension). But for now, no generic is on the shelf.
A Revenue-Sharing Deal Doubles the Overhead
Linzess isn’t sold by one company. Ironwood Pharmaceuticals developed the drug’s active ingredient, linaclotide, and then partnered with what is now AbbVie to commercialize it in the U.S. Under that collaboration agreement, AbbVie records the sales, both companies incur marketing and commercial costs, and the remaining profit is split 50/50. Development costs are also shared equally.
This structure means two companies need to profit from every prescription filled. Both maintain separate R&D operations, sales teams, and corporate overhead tied to the drug. That dual-company model creates financial pressure to keep the list price high enough for both partners to earn meaningful returns. In the first quarter of 2025 alone, Ironwood spent nearly $4 million on linaclotide-related research and development across various formulations and indications.
U.S. Prices Far Exceed International Prices
The price gap between the U.S. and the rest of the world tells a clear story about the role of the American pricing system. At U.S. pharmacies, Linzess 290 mcg runs roughly $8.66 per capsule. The same medication shipped from UK-based pharmacies costs between $4.00 and $5.54 per capsule, a savings of roughly 40 to 55 percent.
This isn’t unique to Linzess. Most countries outside the U.S. have government agencies that negotiate or regulate drug prices. The U.S. largely allows manufacturers to set their own list prices, and Medicare only recently gained limited authority to negotiate on a small number of drugs. The result is that American patients consistently pay more for brand-name medications than patients anywhere else in the world.
Insurance Coverage Varies Widely
How much you actually pay for Linzess depends heavily on your insurance plan and where it falls on your formulary. Many commercial plans place it on a preferred brand tier with a copay of $30 to $75, but others classify it as non-preferred or require prior authorization, meaning your doctor has to justify the prescription before the insurer will cover it. The VA system, for example, lists linaclotide as non-formulary, requiring prior approval and placing it on its highest copay tier.
If you’re uninsured or your plan doesn’t cover Linzess, you’re facing the full retail price. AbbVie does offer savings programs for commercially insured patients, and both AbbVie and Ironwood have patient assistance programs for people who meet certain income and insurance criteria. These can reduce out-of-pocket costs significantly, but they don’t change the underlying list price.
No Cheaper Brand-Name Alternatives Exist
Linzess belongs to a small drug class, and its only direct brand-name competitor, Trulance, is actually more expensive. A 30-day supply of Trulance costs over $617 without insurance, more than double the price of Linzess. Both drugs work through the same mechanism, activating a receptor in the intestinal lining that increases fluid secretion and speeds up gut motility.
Older medications for constipation, like over-the-counter osmotic laxatives, cost a fraction of the price but work differently and aren’t approved for IBS-C. Some doctors will suggest trying those first, partly for cost reasons, before moving to a prescription option. But for patients whose symptoms don’t respond to cheaper treatments, the prescription market offers limited choices, and none of them are affordable without insurance.
When Generic Competition Could Lower Prices
The most meaningful price relief will come when generics enter the market. Based on the Teva settlement, the earliest broad generic competition for the two most commonly prescribed strengths (145 mcg and 290 mcg) is March 2029. The 72 mcg dose could see generic competition as early as 2026 or 2027, depending on pediatric exclusivity extensions and FDA approval timelines.
When generics do arrive, history suggests prices will drop substantially. For most brand-name drugs, the first generic typically costs 20 to 30 percent less, and prices fall further as additional generic manufacturers enter the market. Until then, the combination of patent exclusivity, a two-company profit structure, and the U.S. pricing system will keep Linzess at a premium.